In vivo measurements of the fraction of dose of bleomycin labeled with cobalt 57 delivered to human tumors

D. Front, E. Even-Sapir, O. Israel, G. Iosilevsky, A. Frenkel, David M. Milstein, R. Epelbaum, E. Robinson, G. M. Kolodny

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Concentrations of bleomycin labeled with cobalt 57 (Co-bleo) over time were measured in vivo in 17 patients with 32 sites of lymphoma and 18 patients with lung tumors after administration of the same dose of bleomycin. There were marked variations in individual tumor drug concentrations even among tumors with the same histologic type, indicating that the tumor concentration of this drug in individuals cannot be predicted from the administered dose. Also, tumor concentration could not be predicted from the area under the concentration over time curve (AUC) of Co-bleo in the blood; there was no correlation (r = 0.53) between the AUC and the concentration in the tumor at any point in time between 30 minutes and 8 hours after injection. There was no significant difference in the percent of the injected dose per milliliter (%ID/ml) which was delivered to the tumor when low and high amounts of bleomycin were administered to the same patient. Also, a good correlation (r = 0.88) between the %ID/ml over time was found when injection of low and high doses of bleomycin were compared. The results indicate that using quantitative single photon emission computed tomography (SPECT) and a labeled tracer dose it is possible to predict what fraction of the dose of a chemotherapeutic drug will concentrate in an individual patient's tumor in vivo. They also show that, for bleomycin, escalation of dose will result in a proportional increase of tumor concentration. This increase depends on individual properties of tumors which can be measured quantitatively in vivo by SPECT and are expressed as percent of %ID/ml of tumor tissue.

Original languageEnglish (US)
Pages (from-to)2477-2483
Number of pages7
JournalCancer
Volume67
Issue number10
StatePublished - 1991
Externally publishedYes

Fingerprint

Bleomycin
Cobalt
Neoplasms
Single-Photon Emission-Computed Tomography
Area Under Curve
Pharmaceutical Preparations
Injections
Lymphoma
Lung

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Front, D., Even-Sapir, E., Israel, O., Iosilevsky, G., Frenkel, A., Milstein, D. M., ... Kolodny, G. M. (1991). In vivo measurements of the fraction of dose of bleomycin labeled with cobalt 57 delivered to human tumors. Cancer, 67(10), 2477-2483.

In vivo measurements of the fraction of dose of bleomycin labeled with cobalt 57 delivered to human tumors. / Front, D.; Even-Sapir, E.; Israel, O.; Iosilevsky, G.; Frenkel, A.; Milstein, David M.; Epelbaum, R.; Robinson, E.; Kolodny, G. M.

In: Cancer, Vol. 67, No. 10, 1991, p. 2477-2483.

Research output: Contribution to journalArticle

Front, D, Even-Sapir, E, Israel, O, Iosilevsky, G, Frenkel, A, Milstein, DM, Epelbaum, R, Robinson, E & Kolodny, GM 1991, 'In vivo measurements of the fraction of dose of bleomycin labeled with cobalt 57 delivered to human tumors', Cancer, vol. 67, no. 10, pp. 2477-2483.
Front D, Even-Sapir E, Israel O, Iosilevsky G, Frenkel A, Milstein DM et al. In vivo measurements of the fraction of dose of bleomycin labeled with cobalt 57 delivered to human tumors. Cancer. 1991;67(10):2477-2483.
Front, D. ; Even-Sapir, E. ; Israel, O. ; Iosilevsky, G. ; Frenkel, A. ; Milstein, David M. ; Epelbaum, R. ; Robinson, E. ; Kolodny, G. M. / In vivo measurements of the fraction of dose of bleomycin labeled with cobalt 57 delivered to human tumors. In: Cancer. 1991 ; Vol. 67, No. 10. pp. 2477-2483.
@article{45af724b06df47768caba5a5835da0b1,
title = "In vivo measurements of the fraction of dose of bleomycin labeled with cobalt 57 delivered to human tumors",
abstract = "Concentrations of bleomycin labeled with cobalt 57 (Co-bleo) over time were measured in vivo in 17 patients with 32 sites of lymphoma and 18 patients with lung tumors after administration of the same dose of bleomycin. There were marked variations in individual tumor drug concentrations even among tumors with the same histologic type, indicating that the tumor concentration of this drug in individuals cannot be predicted from the administered dose. Also, tumor concentration could not be predicted from the area under the concentration over time curve (AUC) of Co-bleo in the blood; there was no correlation (r = 0.53) between the AUC and the concentration in the tumor at any point in time between 30 minutes and 8 hours after injection. There was no significant difference in the percent of the injected dose per milliliter ({\%}ID/ml) which was delivered to the tumor when low and high amounts of bleomycin were administered to the same patient. Also, a good correlation (r = 0.88) between the {\%}ID/ml over time was found when injection of low and high doses of bleomycin were compared. The results indicate that using quantitative single photon emission computed tomography (SPECT) and a labeled tracer dose it is possible to predict what fraction of the dose of a chemotherapeutic drug will concentrate in an individual patient's tumor in vivo. They also show that, for bleomycin, escalation of dose will result in a proportional increase of tumor concentration. This increase depends on individual properties of tumors which can be measured quantitatively in vivo by SPECT and are expressed as percent of {\%}ID/ml of tumor tissue.",
author = "D. Front and E. Even-Sapir and O. Israel and G. Iosilevsky and A. Frenkel and Milstein, {David M.} and R. Epelbaum and E. Robinson and Kolodny, {G. M.}",
year = "1991",
language = "English (US)",
volume = "67",
pages = "2477--2483",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - In vivo measurements of the fraction of dose of bleomycin labeled with cobalt 57 delivered to human tumors

AU - Front, D.

AU - Even-Sapir, E.

AU - Israel, O.

AU - Iosilevsky, G.

AU - Frenkel, A.

AU - Milstein, David M.

AU - Epelbaum, R.

AU - Robinson, E.

AU - Kolodny, G. M.

PY - 1991

Y1 - 1991

N2 - Concentrations of bleomycin labeled with cobalt 57 (Co-bleo) over time were measured in vivo in 17 patients with 32 sites of lymphoma and 18 patients with lung tumors after administration of the same dose of bleomycin. There were marked variations in individual tumor drug concentrations even among tumors with the same histologic type, indicating that the tumor concentration of this drug in individuals cannot be predicted from the administered dose. Also, tumor concentration could not be predicted from the area under the concentration over time curve (AUC) of Co-bleo in the blood; there was no correlation (r = 0.53) between the AUC and the concentration in the tumor at any point in time between 30 minutes and 8 hours after injection. There was no significant difference in the percent of the injected dose per milliliter (%ID/ml) which was delivered to the tumor when low and high amounts of bleomycin were administered to the same patient. Also, a good correlation (r = 0.88) between the %ID/ml over time was found when injection of low and high doses of bleomycin were compared. The results indicate that using quantitative single photon emission computed tomography (SPECT) and a labeled tracer dose it is possible to predict what fraction of the dose of a chemotherapeutic drug will concentrate in an individual patient's tumor in vivo. They also show that, for bleomycin, escalation of dose will result in a proportional increase of tumor concentration. This increase depends on individual properties of tumors which can be measured quantitatively in vivo by SPECT and are expressed as percent of %ID/ml of tumor tissue.

AB - Concentrations of bleomycin labeled with cobalt 57 (Co-bleo) over time were measured in vivo in 17 patients with 32 sites of lymphoma and 18 patients with lung tumors after administration of the same dose of bleomycin. There were marked variations in individual tumor drug concentrations even among tumors with the same histologic type, indicating that the tumor concentration of this drug in individuals cannot be predicted from the administered dose. Also, tumor concentration could not be predicted from the area under the concentration over time curve (AUC) of Co-bleo in the blood; there was no correlation (r = 0.53) between the AUC and the concentration in the tumor at any point in time between 30 minutes and 8 hours after injection. There was no significant difference in the percent of the injected dose per milliliter (%ID/ml) which was delivered to the tumor when low and high amounts of bleomycin were administered to the same patient. Also, a good correlation (r = 0.88) between the %ID/ml over time was found when injection of low and high doses of bleomycin were compared. The results indicate that using quantitative single photon emission computed tomography (SPECT) and a labeled tracer dose it is possible to predict what fraction of the dose of a chemotherapeutic drug will concentrate in an individual patient's tumor in vivo. They also show that, for bleomycin, escalation of dose will result in a proportional increase of tumor concentration. This increase depends on individual properties of tumors which can be measured quantitatively in vivo by SPECT and are expressed as percent of %ID/ml of tumor tissue.

UR - http://www.scopus.com/inward/record.url?scp=0025917342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025917342&partnerID=8YFLogxK

M3 - Article

C2 - 1707747

AN - SCOPUS:0025917342

VL - 67

SP - 2477

EP - 2483

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -